Abstract 1697
Background
The patients’ (pts) illness perception is based on dimensions of cognitive understanding and emotional representations of disease and its symptoms. Previous studies reported that illness perceptions influence quality of life (QoL) and mood.
Methods
212 pts with metastatic breast cancer, under treatment, were evaluated by Illness Perception Questionnaire Brief version (IPQ-B), EORTC Quality of Life Questionnaire (QLQ-30) and Hospital Anxiety and Depression Scale (HADS). IPQ-B higher scores indicate a negative perception. EORTC QLQ-30 higher scores indicate better functioning/QoL or worse symptom severity. Higher HADS indicate higher anxiety/depression (AD) levels. Variables were studied using Pearls correlation (Sig 0.01) and T test. Primary endpoint was evaluation of illness perception. Secondary endpoints were assessment of pts characteristics, QoL, AD and its associations with illness perception.
Results
Median age was 64 years (y) and 99.5% (211 pts) were women. Median IPQ-B score was 18/32. All patients reported that their breast cancer is incurable. Perception of disease consequences was more negative in pts younger than 70y versus 70y or older (2.7 vs 2.3, p = 0.039). Preoccupation and perception of control with treatment were higher in younger pts (3.4 vs 2.9, p = 0.004; 3.6 vs 3.3, p = 0.03; respectively). Pts under chemotherapy and/or anti-HER2 therapy shown a greater impact of disease consequences, than pts under endocrine therapy and/or other target therapies (2.6 vs 2.3, p = 0.039). The mean overall QoL was 54.6/100 (± 23.0). Physical, cognitive, social and emotional functioning mean scores were respectively 60.3, 69.1, 69.3 and 60.3/100; all lower than EORTC ref. values (p < 0.01). Social functioning and IPQ-B shown a moderate negative correlation (r = - 0.507). The mean HADS score was 16.9/42 (± 7.8), reflecting the AD subscales (respectively, 9.1/21; 7.8/21). The overall illness perception and HADS shown a moderate positive association (r = 0.62). Anxiety and the emotional dimension of IPQ-B had a moderate positive correlation (r = 0.598).
Conclusions
Integrating in clinical practice the relation between illness perceptions, QoL and AD, may improve disease’s coping mechanisms and functional capacity (physical, emotional, social).
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5887 - Factors of importance in procuring tumoroids from colorectal liver metastasis biopsies for precision medicine.
Presenter: Lars Henrik Jensen
Session: Poster Display session 2
Resources:
Abstract
2196 - FUSAFE individual patient data meta-analysis (MA) to assess the performance of dihydropyrimidine dehydrogenase (DPD) gene polymorphisms for predicting grade 4-5 fluoropyrimidine (FP) toxicity
Presenter: Marie-Christine Etienne-Grimaldi
Session: Poster Display session 2
Resources:
Abstract
2859 - Treatments (tx) after progression to first-line FOLFOXIRI + bevacizumab (bev) in metastatic colorectal cancer (mCRC) patients (pts): A pooled analysis of TRIBE and TRIBE-2 studies by GONO.
Presenter: Daniele Rossini
Session: Poster Display session 2
Resources:
Abstract
3888 - Randomized phase III study of sequential treatment with capecitabine or 5-fluorouracil (FP) plus bevacizumab (BEV) followed by the addition with oxaliplatin (OX) versus initial combination with OX+FP+ BEV in the first-line chemotherapy for metastatic colorectal cancer: The C-cubed study
Presenter: Takeshi Nagasaka
Session: Poster Display session 2
Resources:
Abstract
1065 - Early tumour shrinkage (ETS), depth of response (DpR) and associated survival outcomes in patients (pts) with RAS wild type (WT) metastatic colorectal cancer (mCRC) classified according to Köhne prognostic category: retrospective analysis of the panitumumab (Pmab) PRIME study
Presenter: Andrea Sartore-Bianchi
Session: Poster Display session 2
Resources:
Abstract
1702 - Randomized phase II trial of CAPOX with planned oxaliplatin stop-and-go strategy as adjuvant chemotherapy after curative resection of colon cancer (CCOG-1302 study)
Presenter: Hiroyuki Yokoyama
Session: Poster Display session 2
Resources:
Abstract
5104 - A metabolomic recurrence score for risk-stratification of elderly patients (pts) with early colorectal cancer (eCRC)
Presenter: Samantha Di Donato
Session: Poster Display session 2
Resources:
Abstract
5285 - RAS mutant allele fraction in plasma predicts benefit to anti-angiogenic based first line treatment in metastatic colorectal cancer
Presenter: Giulia Martini
Session: Poster Display session 2
Resources:
Abstract
1790 - Impact of prophylactic systemic antibiotics (SA) on outcome of patients (pts) with RAS-wildtype (RAS-wt) metastatic colorectal carcinoma (mCRC) treated with cetuximab-based first-line therapy. Subgroup analysis of the german non-interventional study ERBITAG
Presenter: Stephan Sahm
Session: Poster Display session 2
Resources:
Abstract
3059 - Intraoperative chemotherapy with 5-FU for colorectal cancer patients receiving curative resection (IOCCRC): A randomized, multicenter, prospective, phase III trial
Presenter: Rongxin Zhang
Session: Poster Display session 2
Resources:
Abstract